

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

**FORM 10-Q**

☒ **QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the Quarterly Period Ended June 30, 2023**

or

☐ **TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the Transition Period from \_\_\_\_\_ to \_\_\_\_\_**

**Commission file number: 001-37603**

**BIORESTORATIVE THERAPIES, INC.**

(Exact name of registrant as specified in its charter)

**Nevada**

(State or other Jurisdiction of  
Incorporation or Organization)

**30-1341024**

(I.R.S. Employer  
Identification No.)

**40 Marcus Drive, Melville, New York**  
(Address of Principal Executive Offices)

**11747**  
(Zip Code)

**(631) 760-8100**

(Registrant's telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

<b>Title of each class</b>	<b>Trading symbol(s)</b>	<b>Name of exchange on which registered</b>
Common Stock, \$0.0001 par value	BRTX	Nasdaq Capital Market

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company" and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer	<input type="checkbox"/>	Accelerated filer	<input type="checkbox"/>
Non-accelerated filer	<input checked="" type="checkbox"/>	Smaller reporting company	<input checked="" type="checkbox"/>
		Emerging growth company	<input type="checkbox"/>

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act: ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate by checkmark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes ☒ No ☐

As of August 8, 2023 there were 4,667,641 shares of the registrant's Common Stock outstanding.

**BIORESTORATIVE THERAPIES, INC. AND SUBSIDIARY**  
**FORM 10-Q**  
**FOR THE THREE AND SIX MONTHS ENDED JUNE 30, 2023 AND 2022**

**TABLE OF CONTENTS**

	<b>Page</b>
<b><u>PART I. FINANCIAL INFORMATION</u></b>	<b>3</b>
ITEM 1. <a href="#"><u>Financial Statements</u></a>	3
<a href="#"><u>Condensed Consolidated Balance Sheets as of June 30, 2023 (unaudited) and December 31, 2022</u></a>	3
<a href="#"><u>Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2023 and 2022 (unaudited)</u></a>	4
<a href="#"><u>Condensed Consolidated Statements of Changes in Stockholders' Equity for the Three and Six Months Ended June 30, 2023 and 2022 (unaudited)</u></a>	5
<a href="#"><u>Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2023 and 2022 (unaudited)</u></a>	6
<a href="#"><u>Notes to Condensed Consolidated Financial Statements (unaudited)</u></a>	7
ITEM 2. <a href="#"><u>Management's Discussion and Analysis of Financial Condition and Results of Operations</u></a>	16
ITEM 3. <a href="#"><u>Quantitative and Qualitative Disclosures about Market Risk</u></a>	22
ITEM 4. <a href="#"><u>Controls and Procedures</u></a>	22
<b><u>PART II. OTHER INFORMATION</u></b>	<b>23</b>
ITEM 1A. <a href="#"><u>Risk Factors</u></a>	23
ITEM 2. <a href="#"><u>Unregistered Sales of Equity Securities and Use of Proceeds</u></a>	23
ITEM 6. <a href="#"><u>Exhibits</u></a>	24
<b><u>SIGNATURES</u></b>	<b>24</b>

**PART I - FINANCIAL INFORMATION**

**ITEM 1. FINANCIAL STATEMENTS**

**BIORESTORATIVE THERAPIES, INC. AND SUBSIDIARY  
CONDENSED CONSOLIDATED BALANCE SHEETS**

	<b>June 30, 2023</b>	<b>December 31, 2022</b>
	<i>(Unaudited)</i>	
<b>ASSETS</b>		
<b>Current Assets:</b>		
Cash and cash equivalents	\$ 1,783,646	\$ 1,676,577
Investments held in marketable securities	9,831,719	13,072,831
Accounts receivable	25,000	16,000
Prepaid expenses and other current assets	403,559	363,082
<b>Total Current Assets</b>	<b>12,043,924</b>	<b>15,128,490</b>
Property and equipment, net	314,070	261,003
Right of use asset	183,738	241,760
Intangible assets, net	758,565	803,438
<b>Total Assets</b>	<b>\$ 13,300,297</b>	<b>\$ 16,434,691</b>
<b>LIABILITIES AND STOCKHOLDERS' EQUITY</b>		
<b>Current Liabilities:</b>		
Accounts payable	\$ 276,048	\$ 170,902
Accrued expenses and other current liabilities	386,325	130,072
Lease liability, current portion	150,480	139,328
<b>Total Current Liabilities</b>	<b>812,853</b>	<b>440,302</b>
Lease liability, net of current portion	83,580	162,317
<b>Total Liabilities</b>	<b>896,433</b>	<b>602,619</b>
<b>Stockholders' Equity</b>		
Preferred stock, \$0.01 par value; Authorized, 20,000,000 shares; Series B Convertible Preferred Stock, \$0.01 par value; 1,543,158 designated shares, 1,398,158 and 1,518,158 issued and outstanding at June 30, 2023 and December 31, 2022, respectively	13,982	15,182
Common Stock, \$0.0001 par value; Authorized, 75,000,000 shares; 3,982,608 and 3,677,775 issued and outstanding at June 30, 2023 and December 31, 2022, respectively	399	369
Additional paid in capital	173,695,154	168,457,418
Accumulated deficit	(161,305,671)	(152,640,897)
<b>Total Stockholders' Equity</b>	<b>12,403,864</b>	<b>15,832,072</b>
<b>Total Liabilities and Stockholders' Equity</b>	<b>\$ 13,300,297</b>	<b>\$ 16,434,691</b>

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

**BIORESTORATIVE THERAPIES, INC. AND SUBSIDIARY**  
**CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS**  
(Unaudited)

	For the Three Months Ended,		For the Six Months Ended,	
	June 30, 2023	June 30, 2022	June 30, 2023	June 30, 2022
<b>Revenues</b>	\$ 64,500	\$ 71,100	\$ 95,800	\$ 87,100
<b>Operating expenses:</b>				
Research and development	967,891	1,075,224	2,479,136	1,850,561
General and administrative	2,213,160	3,624,504	6,512,313	7,918,960
Total operating expenses	3,181,051	4,699,728	8,991,449	9,769,521
Loss from operations	(3,116,551)	(4,628,628)	(8,895,649)	(9,682,421)
<b>Other (income) expense:</b>				
Interest (income) expense	(96,187)	46,613	(114,403)	75,624
Gain on PPP loan forgiveness	-	-	-	(250,000)
Grant income	-	-	-	(16,654)
Other income, net	(39,812)	-	(116,472)	-
Total other (income) expense	(135,999)	46,613	(230,875)	(191,030)
<b>Net loss</b>	<u>\$ (2,980,552)</u>	<u>\$ (4,675,241)</u>	<u>\$ (8,664,774)</u>	<u>\$ (9,491,391)</u>
Net Loss Per Share - Basic and Diluted	\$ (0.77)	\$ (1.28)	\$ (2.28)	\$ (2.65)
Weighted Average Number of Common Shares Outstanding - Basic and Diluted	3,886,309	3,638,383	3,803,323	3,581,110

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

**BIORESTORATIVE THERAPIES, INC. AND SUBSIDIARY**  
**CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY**  
(Unaudited)

	Series B Convertible Preferred Stock		Common Stock		Additional Paid-in Capital	Accumulated Deficit	Total Stockholders' Equity
	Shares	Amount	Shares	Amount			
<b>Balance at January 1, 2023</b>	1,518,158	\$ 15,182	3,677,775	\$ 369	\$ 168,457,418	\$ (152,640,897)	\$ 15,832,072
Stock-based compensation:							
- restricted share units	-	-	89,840	9	1,148,750	-	1,148,759
- options	-	-	-	-	2,190,428	-	2,190,428
- common stock	-	-	-	-	-	-	-
Net loss	-	-	-	-	-	(5,684,222)	(5,684,222)
<b>Balance as of March 31, 2023</b>	<u>1,518,158</u>	<u>\$ 15,182</u>	<u>3,767,615</u>	<u>\$ 378</u>	<u>\$ 171,796,596</u>	<u>\$ (158,325,119)</u>	<u>\$ 13,487,037</u>
Stock-based compensation:							
- restricted share units	-	-	1,442	-	1,164,135	-	1,164,135
- options	-	-	-	-	321,534	-	321,534
- common stock	-	-	-	-	-	-	-
Issuance of common stock	-	-	93,551	9	411,701	-	411,710
Conversion of Series B preferred to common stock	(120,000)	(1,200)	120,000	12	1,188	-	-
Net loss	-	-	-	-	-	(2,980,552)	(2,980,552)
<b>Balance as of June 30, 2023</b>	<u>1,398,158</u>	<u>\$ 13,982</u>	<u>3,982,608</u>	<u>\$ 399</u>	<u>\$ 173,695,154</u>	<u>\$ (161,305,671)</u>	<u>\$ 12,403,864</u>
<b>Balance at January 1, 2022</b>	-	\$ -	3,520,391	\$ 353	\$ 155,727,292	\$ (134,146,128)	\$ 21,596,949
Stock-based compensation:							-
- restricted share units	-	-	97,828	10	1,164,125	-	1,164,135
- options	-	-	-	-	2,138,949	-	2,138,949
- common stock	-	-	13,500	1	72,818	-	72,819
Net loss	-	-	-	-	-	(4,816,150)	(4,816,150)
<b>Balance at March 31, 2022</b>	<u>-</u>	<u>\$ -</u>	<u>3,631,719</u>	<u>\$ 364</u>	<u>\$ 159,103,184</u>	<u>\$ (138,962,278)</u>	<u>\$ 20,156,702</u>
Stock-based compensation:							
- restricted share units	-	-	6,220	1	1,190,349	-	1,190,350
- options	-	-	-	-	1,865,297	-	1,865,297
- common stock	-	-	5,770	-	48,504	-	48,504
Net loss	-	-	-	-	-	(4,675,241)	(4,675,241)
<b>Balance as of June 30, 2022</b>	<u>-</u>	<u>\$ -</u>	<u>3,643,709</u>	<u>\$ 365</u>	<u>\$ 162,207,334</u>	<u>\$ (143,637,519)</u>	<u>\$ 18,585,612</u>

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

**BIORESTORATIVE THERAPIES, INC. AND SUBSIDIARY**  
**CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS**  
(Unaudited)

	<b>Six Months Ended</b>	
	<b>June 30, 2023</b>	<b>June 30, 2022</b>
	<i>(Unaudited)</i>	
Cash flows from operating activities:		
Net Loss	\$ (8,664,774)	\$ (9,491,391)
Adjustments to reconcile net loss to net cash used in operating activities:		
Depreciation and amortization	80,877	57,526
Unrealized gain on marketable securities	(22,392)	-
Stock-based compensation	4,824,865	6,480,055
Gain on PPP loan forgiveness	-	(250,000)
Non-cash lease expense	58,022	58,022
Changes in operating assets and liabilities:		
Accounts receivable	(9,000)	(11,000)
Prepaid assets and other current assets	(40,477)	61,688
Accounts payable	105,146	327,406
Accrued expenses and other current liabilities	256,253	(20,311)
Lease liability	(67,585)	(57,751)
Net cash used in operating activities	<u>(3,479,065)</u>	<u>(2,845,756)</u>
Cash flows from investing activities:		
Sale of marketable securities	3,263,504	-
Purchases of equipment	(89,071)	(247,247)
Net cash provided by (used in) investing activities	<u>3,174,433</u>	<u>(247,247)</u>
Cash flows from financing activities:		
Net proceeds from issuance of common stock in at-the-market offering	411,701	-
Net cash provided by financing activities	<u>411,701</u>	<u>-</u>
Net increase (decrease) in cash and cash equivalents	107,069	(3,093,003)
Cash and cash equivalents - beginning of period	1,676,577	21,026,727
Cash and cash equivalents - end of period	<u>\$ 1,783,646</u>	<u>\$ 17,933,724</u>
Supplemental cash flow information:		
Cash paid for:		

The accompanying footnotes are an integral part of these unaudited condensed consolidated financial statements.

**BIORESTORATIVE THERAPIES, INC.**  
**NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS**  
**(Unaudited)**

**NOTE 1 - NATURE OF THE ORGANIZATION, LIQUIDITY, AND BUSINESS**

*Corporate History*

BioRestorative Therapies, Inc. has one wholly-owned subsidiary, Stem Pearls, LLC (“Stem Pearls”). BioRestorative Therapies, Inc. and its subsidiary are referred to collectively as “BRT” or the “Company”.

On December 29, 2022, the Company reincorporated from Delaware to Nevada. The reincorporation was structured as a statutory merger of BioRestorative Therapies, Inc., a Delaware corporation, with and into its wholly-owned subsidiary, BioRestorative Therapies, Inc., a Nevada corporation.

*Liquidity*

The accompanying condensed consolidated financial statements have been prepared on the basis that the Company will continue as a going concern, which contemplates realization of assets and satisfying liabilities in the normal course of business. For the six months ended June 30, 2023, the Company had a net loss of \$8.7 million (of which, \$4.8 million was attributable to non-cash stock-based compensation) and negative cash flows from operations of \$3.5 million. The Company’s operating activities consume the majority of its cash resources. The Company anticipates that it will continue to incur net losses as it executes its development plans throughout 2023 and beyond, as well as other potential strategic and business development initiatives. In addition, the Company has had and expects to have negative cash flows from operations, at least into the near future. The Company has previously funded, and plans to continue funding, these losses primarily through current cash on hand, investments in marketable securities and additional infusions of cash from equity and debt financing.

On April 14, 2023, the Company entered into a sales agreement with JonesTrading Institutional Services LLC for an at-the-market (“ATM”) offering of the Company’s Common Stock, par value \$0.0001 per share, at an aggregate offering price of up to \$3.7 million. During the three months ended June 30, 2023, net proceeds of \$411,710 were received from the issuance of 93,551 shares of Common Stock.

On July 13, 2023, the Company sold an aggregate of 685,033 shares of Common Stock to several institutional buyers and accredited investors in a registered direct offering at an offering price of \$3.03 per share. The offering closed on July 13, 2023, with net proceeds of approximately \$1.8 million. The Company intends to use the net proceeds from the offering in connection with its clinical trials with respect to its lead cell therapy candidate, *BRTX-100*, pre-clinical research and development with respect to its metabolic *ThermoStem Program* and for general corporate purposes and working capital.

Based on cash on hand as of June 30, 2023, the Company believes it has sufficient cash to fund operations for the twelve months subsequent to the filing date of this Form 10-Q.

Current funds noted above will not be sufficient to enable the Company to fully complete its development activities or attain profitable operations. If the Company is unable to obtain such needed additional financing on a timely basis, the Company may have to curtail its development, marketing and promotional activities, which would have a material adverse effect on the Company’s business, financial condition and results of operations, and ultimately the Company could be forced to discontinue its operations and liquidate.

The accompanying condensed consolidated financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America ("GAAP"), which contemplate continuation of the Company as a going concern and the realization of assets and satisfaction of liabilities in the normal course of business. The carrying amounts of assets and liabilities presented in the condensed consolidated financial statements do not necessarily purport to represent realizable or settlement values. The accompanying condensed consolidated financial statements do not include any adjustments that might be necessary should the Company be unable to continue as a going concern.

#### *Business Operations*

BRT develops therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult stem cells. BRT's website is at [www.biorestorative.com](http://www.biorestorative.com). The information contained in our website is not intended to be incorporated by reference into this Quarterly Report. BRT is currently developing a Disc/Spine Program referred to as "brtxDISC". Its lead cell therapy candidate, *BRTX-100*, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. The product is intended to be used for the non-surgical treatment of painful lumbosacral disc disorders or as a complimentary therapeutic to a surgical procedure. BRT is investigating the expansion of the clinic application of *BRTX-100* to other indications within the body. BRT is also engaging in research efforts with respect to a platform technology utilizing brown adipose (fat) for therapeutic purposes to treat type 2 diabetes, obesity and other metabolic disorders and has labeled this initiative its ThermoStem Program. Further, BRT has licensed a patented curved needle device that is a needle system designed to deliver cells and/or other therapeutic products or material to the spine and discs or other potential sites.

## **NOTE 2 – BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

#### *Basis of Presentation*

The accompanying condensed consolidated financial statements have been prepared in accordance with GAAP. The summary of significant accounting policies presented below is designed to assist in understanding the Company's condensed consolidated financial statements.

The condensed consolidated financial statements of the Company included herein have been prepared, pursuant to the rules and regulations of the Securities and Exchange Commission (the "SEC"). Certain information and footnote disclosures normally included in financial statements prepared in accordance with GAAP have been condensed or omitted from this report, as is permitted by such rules and regulations. Accordingly, these condensed consolidated financial statements should be read in conjunction with the consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2022, filed with the SEC on March 27, 2023 (the "Annual Report"). The summary of significant accounting policies presented below is designed to assist in understanding the Company's condensed consolidated financial statements. Such condensed consolidated financial statements and accompanying notes are the representations of Company's management, who is responsible for their integrity and objectivity. Operating results for the three and six months ended June 30, 2023 are not necessarily indicative of the results that may be expected for the entire year or for any other subsequent interim period.

#### *Principles of Consolidation*

The condensed consolidated financial statements include the accounts of the Company and its wholly-owned subsidiary. All intercompany accounts and transactions have been eliminated upon consolidation.

#### *Use of Estimates*

The preparation of the condensed consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, equity-based transactions, revenue and expenses and disclosure of contingent liabilities at the date of the condensed consolidated financial statements. The Company bases its estimates and assumptions on historical experience, known or expected trends and various other assumptions that it believes to be reasonable. As future events and their effects cannot be determined with precision, actual results could differ from these estimates which may cause the Company's future results to be affected.



### *Concentrations*

Financial instruments that potentially subject the Company to concentrations of credit risk consist of a cash account in a financial institution. The Company maintains deposits in its cash account in excess of the Federal Deposit Insurance Corporation coverage of \$250,000. As of June 30, 2023, the Company has not experienced losses on this account.

The royalties related to the Company's sublicense comprised all of the Company's revenue during the three and six months ended June 30, 2023 and 2022.

### *Summary of Significant Accounting Policies*

The Company's significant accounting policies are described in Note 2, Summary of Significant Accounting Policies and Recent Accounting Standards, in the Annual Report. During the three and six months ended June 30, 2023, the Company did not make any changes to its significant accounting policies, except as described below with respect to recent accounting pronouncements.

### *Fair Value Measurements*

As defined in ASC 820, *Fair Value Measurements and Disclosures* ("ASC 820"), fair value is the price that would be received for an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (exit price). The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability, including assumptions about risk and the risks inherent in the inputs to the valuation technique. These inputs can be readily observable, market corroborated, or generally unobservable. ASC 820 establishes a fair value hierarchy that prioritizes the inputs used to measure fair value. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (level 1 measurement) and the lowest priority to unobservable inputs (level 3 measurement). This fair value measurement framework applies at both initial and subsequent measurement.

- Level 1: Quoted prices are available in active markets for identical assets or liabilities as of the reporting date. Active markets are those in which transactions for the asset or liability occur in sufficient frequency and volume to provide pricing information on an ongoing basis. Level 1 primarily consists of financial instruments such as exchange-traded derivatives, marketable securities and listed equities.
- Level 2: Pricing inputs are other than quoted prices in active markets included in Level 1, which are either directly or indirectly observable as of the reported date. Level 2 includes those financial instruments that are valued using models or other valuation methodologies. These models are primarily industry-standard models that consider various assumptions, including quoted forward prices for commodities, time value, volatility factors and current market and contractual prices for the underlying instruments, as well as other relevant economic measures. Substantially all of these assumptions are observable in the marketplace throughout the full term of the instrument, can be derived from observable data or are supported by observable levels at which transactions are executed in the marketplace. Instruments in this category generally include non-exchange-traded derivatives such as commodity swaps, interest rate swaps, options and collars.
- Level 3: Pricing inputs include significant inputs that are generally less observable from objective sources. These inputs may be used with internally-developed methodologies that result in management's best estimate of fair value.

	Fair value measurements at reporting date using:			
	Fair value	Quoted prices in active markets for identical liabilities (Level 1)	Significant other observable inputs (Level 2)	Significant unobservable inputs (Level 3)
Assets:				
Marketable securities as of June 30, 2023	\$ 9,831,719	\$ 9,831,719	-	-
Marketable securities as of December 31, 2022	\$ 13,072,831	\$ 13,072,831	-	-

#### *Fair Value of Financial Instruments*

The carrying value of cash, accounts receivable, and accounts payable approximate their fair values based on the short-term maturity of these instruments.

#### *Net Loss per Common Share*

Net loss per share is computed by dividing net loss by the weighted average number of shares of Common Stock outstanding during the year. All outstanding options and warrants are considered potential Common Stock. The dilutive effect, if any, of stock options and warrants are calculated using the treasury stock method. All outstanding convertible preferred stock is considered Common Stock at the beginning of the period or at the time of issuance, if later, pursuant to the if-converted method. Since the effect of Common Stock equivalents is anti-dilutive with respect to losses, options, warrants, and convertible preferred stock have been excluded from the Company's computation of diluted net loss per common share for the three and six months ended June 30, 2023 and 2022.

The following tables summarize the securities that were excluded from the diluted per share calculation because the effect of including these potential shares was antidilutive due to the Company's net loss position even though the exercise or conversion price could be less than the average market price of the common shares:

	Three Months Ended June 30,	
	2023	2022
Options	1,466,890	864,609
Warrants	4,791,072	4,739,733
Unvested RSUs	97,827	214,303
Convertible preferred stock	1,398,158	-
Total	7,753,947	5,818,645

  

	Six Months Ended June 30,	
	2023	2022
Options	1,466,890	864,609
Warrants	4,791,072	4,739,733
Unvested RSUs	97,827	214,303
Convertible preferred stock	1,398,158	-
Total	7,753,947	5,818,645

## Recently Adopted Accounting Pronouncements

In June 2016, the FASB issued ASU 2016-13, *Financial Instruments - Credit Losses*, which requires entities to estimate all expected credit losses for financial assets measured at amortized cost basis, including trade receivables, held at the reporting date based on historical experience, current conditions, and reasonable and supportable forecasts. The Company adopted this guidance on January 1, 2023. The adoption of this accounting standard did not have a material impact on the Company's condensed consolidated financial statements.

## NOTE 3 - INTANGIBLE ASSETS

The Company is a party to a license agreement with a stem cell treatment company (the "SCTC") (as amended) (the "SCTC Agreement"). Pursuant to the SCTC Agreement, the Company obtained, among other things, a worldwide, exclusive, royalty-bearing license from the SCTC to utilize or sublicense a certain medical device patent for the administration of specific cells and/or cell products to the disc and/or spine (and other parts of the body) and a worldwide (excluding Asia and Argentina), exclusive, royalty-bearing license to utilize or sublicense a certain method for culturing cells. Pursuant to the license agreement with the SCTC, certain performance milestones (or payouts in lieu of performance milestones) had to be satisfied in order for the Company to maintain its exclusive rights with regard to the disc/spine technology. The Company did not timely satisfy the third of these performance milestones (which needed to be satisfied by February 2022). Accordingly, such rights became non-exclusive. However, in November 2022, the Company entered into an amended agreement under which it paid \$175,000 and issued 51,370 warrants, with a fair value of \$117,030, in exchange for renewed exclusivity. The consideration transferred to the SCTC in exchange for exclusivity was capitalized to intangible assets on the Company's consolidated balance sheet as of December 31, 2022.

In February 2017, the Company received authorization from the Food and Drug Administration (the "FDA") to proceed with a Phase 2 clinical trial. In March 2022, the United States Patent and Trademark Office issued a patent relating to the Company's BRTX-100 clinical program.

Intangible assets consist of the following:

	Patents and Trademarks	Licenses	Accumulated Amortization	Total
Balance as of January 1, 2023	\$ 3,676	\$ 1,593,530	\$ (793,768)	\$ 803,438
Amortization expense	-	-	(44,873)	(44,873)
Balance as of June 30, 2023	\$ 3,676	\$ 1,593,530	\$ (838,641)	\$ 758,565
Weighted average remaining amortization period as of June 30, 2023	-	10.75		

Accumulated amortization of intangible assets consists of the following:

	Patents and Trademarks	Licenses	Accumulated Amortization
Balance as of January 1, 2023	\$ 3,676	\$ 790,092	\$ 793,768
Amortization expense	-	44,873	44,873
Balance as of June 30, 2023	\$ 3,676	\$ 834,965	\$ 838,641

## NOTE 4 - ACCRUED EXPENSES AND OTHER CURRENT LIABILITIES

Accrued expenses and other current liabilities consist of:

	June 30, 2023	December 31, 2022
Accrued payroll	\$ 325,000	\$ 26,250
Accrued general and administrative expenses	61,325	103,822
	\$ 386,325	\$ 130,072

## NOTE 5 - STOCKHOLDERS' EQUITY

### *Series A Preferred Stock*

On November 8, 2021, in connection with the Company's public offering, the Company's Board of Directors adopted a resolution allowing for the designation and issuance of 1,543,158 shares of the Company's Preferred Stock, \$.01 par value per share, designated as Series A Preferred Stock ("Series A"). The Series A had a liquidation preference of \$0.001 per share. On September 8, 2022, the Company issued 1,543,158 shares of Series B Preferred Stock ("Series B") to Auctus Fund, LLC ("Auctus") in exchange for an equal number of shares of the Company's outstanding Series A. Simultaneously, the stock certificate representing the Series A shares was being returned to the Company for cancellation. On such date and upon such exchange, the Company's Board of Directors cancelled the Series A.

### *Series B Preferred Stock*

Effective September 8, 2022, the Company issued 1,543,158 shares of Series B to Auctus in exchange for an equal number of shares of the Company's outstanding Series A. The terms of the Series B are substantially identical to those of the Series A, except that, among other things, the limitation on beneficial ownership of Common Stock of the Company upon a conversion of the Series B into Common Stock, and the limitation on the number of votes attributable to the Series B, is 9.99% of the then outstanding Common Stock of the Company instead of 4.99% as provided for the Series A. The Company shall, at all times, reserve from its authorized and unissued Common Stock a sufficient number of shares to provide for the issuance of Common Stock upon the full conversion of the Series B. The Series B is not subject to redemption by the Company or any Series B holder.

### Dividends

Series B holders shall be entitled to receive, when and as declared by the Board of Directors, dividends on a pari passu basis with the holders of the shares of Common Stock based upon the number of shares of Common Stock into which the Series B is then convertible.

### Voting Rights

Series B holders shall be entitled to vote on all matters presented to the stockholders of the Company for a vote at a meeting of stockholders of the Company or a written consent in lieu of a meeting of stockholders of the Company, and shall be entitled to such number of votes for each share of Series B entitled to vote at such meetings or pursuant to such consent, voting together with the holders of shares of Common Stock and other shares of preferred stock who are entitled to vote, and not as a separate class, except as required by law. The number of votes to which the Series B holders shall be entitled to vote for each share of Series B shall equal the number of shares of Common Stock into which such Series B is then convertible; provided, however, that in no event shall a Series B holder be entitled to vote more than 9.99% of the then outstanding shares of Common Stock.

### Conversion

Optional Conversion - Each share of Series B shall be convertible, at any time and from time to time, at the option of the Series B holder, into one share of Common Stock; provided, however, that in no event shall a Series B holder be entitled to convert any shares of Series B to the extent that such conversion would result in beneficial ownership by such Series B holder of more than 9.99% of the outstanding shares of Common Stock.

Automatic Conversion – From time to time, if an event occurs, including adjustment due to merger, consolidation, etc., subdivision or combination of Common Stock, adjustment due to distribution, purchase rights, and notice of adjustments, which has the effect of reducing a Series B holder's beneficial ownership of shares of Common Stock to less than 9.5% of the then publicly disclosed outstanding shares of Common Stock, then, within five (5) business days, the Series B holder shall provide notice to the Company to such effect, which notice shall state the number of shares of Common Stock beneficially owned by the Series B holder and shall provide reasonable detail with regard thereto, including the number of derivative securities comprising a portion of such beneficial share amount. Such notice shall have the effect of a notice of conversion with respect to the conversion of such number of shares of Series B as would increase the Series B holder's beneficial ownership of Common Stock to 9.99% of the then publicly disclosed outstanding shares of Common Stock.

On April 4, 2023, Auctus converted 120,000 shares of Series B into 120,000 shares of Common Stock. As of June 30, 2023, the number of shares of Series B remaining outstanding after giving effect to such conversion was 1,398,158.

#### *Warrant and Option Valuation*

The Company has computed the fair value of warrants and options granted using the Black-Scholes option pricing model. The expected term used for warrants and options issued to non-employees is the contractual life and the expected term used for options issued to employees and directors is the estimated period of time that options granted are expected to be outstanding. The Company utilizes the “simplified” method to develop an estimate of the expected term of “plain vanilla” employee option grants. The Company is utilizing an expected volatility figure based on a review of the historical volatilities, over a period of time equivalent to the expected life of the instrument being valued, of similarly positioned public companies within its industry. The risk-free interest rate was determined from the implied yields from U.S. Treasury zero-coupon bonds with a remaining term consistent with the expected term of the instrument being valued.

#### *Stock Options*

There were no stock options granted during the three months ended June 30, 2023. The Company granted options for the purchase of 629,017 shares of Common Stock during the six months ended June 30, 2023. The grant date fair value of options issued during the six months ended June 30, 2023 was \$1,745,000.

There were no stock options granted during the three months ended June 30, 2022. The Company granted options for the purchase of 25,000 shares of Common Stock during the six months ended June 30, 2022. The grant date fair value of options issued during the six months ended June 30, 2022 was \$122,117.

In applying the Black-Scholes option pricing model to stock options granted during the six months ended June 30, 2023, the Company used the following assumptions:

	<b>For the Six Months Ended June 30, 2023</b>	<b>For the Six Months Ended June 30, 2022</b>
Risk free interest rate	4.22%	2.42%
Expected term (years)	3.50	3.50
Expected volatility	175%	286%
Expected dividends	0.00%	0.00%

A summary of the stock option activity during the six months ended June 30, 2023 is presented below:

	<b>Number of Options</b>	<b>Weighted Average Exercise Price</b>
Outstanding, January 1, 2023	864,639	\$ 5.08
Granted	629,017	2.91
Expired	-	—
Forfeited	(26,766)	5.08
Outstanding, June 30, 2023	1,466,890	\$ 4.17
Exercisable, June 30, 2023	1,041,062	\$ 4.66

### Restricted Stock Units

Pursuant to the Company's 2021 Stock Incentive Plan (the "2021 Plan"), the Company may grant restricted stock units ("RSUs") to employees, consultants or non-employee directors ("Eligible Individuals"). The number, terms and conditions of the RSUs that are granted to Eligible Individuals are determined on an individual basis by the 2021 Plan administrator. On the distribution date, the Company shall issue to the Eligible Individual one unrestricted, fully transferable share of the Company's Common Stock (or the fair market value of one such share in cash) for each vested and nonforfeitable RSU.

A summary of the Company's unvested RSUs as of June 30, 2023 is as follows:

	Number of Shares
Outstanding, December 31, 2022	201,870
Granted	-
Forfeited	-
Vested	(104,043)
Outstanding, June 30, 2023	97,827

The following table presents stock compensation by award type:

	For the Three Months Ended June 30,	
	2023	2022
Options	\$ 321,534	\$ 1,865,297
RSUs	1,164,135	1,190,349
Shares issued for services	-	48,504
	\$ 1,485,669	\$ 3,104,150

  

	For the Six Months Ended June 30,	
	2023	2022
Options	\$ 2,511,962	\$ 4,004,246
RSUs	2,312,885	2,354,474
Shares issued for services	-	121,322
	\$ 4,824,847	\$ 6,480,042

Stock based compensation is included in General and administrative expenses on the consolidated statements of operations. As of June 30, 2023, unrecognized stock based compensation expense is \$1,201,875 with a weighted average remaining amortization period of 1.04 years.

### NOTE 6 - LEASES

The Company is a party to a lease for 6,800 square feet of space located in Melville, New York (the "Melville Lease") with respect to its corporate and laboratory operations. The Melville Lease was scheduled to expire in March 2020 (subject to extension at the option of the Company for a period of five years) and provided for an annual base rental during the initial term ranging between \$132,600 and \$149,260. In June 2019, the Company exercised its option to extend the Melville Lease and entered into a lease amendment with the lessor whereby the five-year extension term commenced on January 1, 2020 with annual base rent ranging between \$153,748 and \$173,060.

When measuring lease liabilities for leases that were classified as operating leases, the Company discounted lease payments using its estimated incremental borrowing rate at August 1, 2019. The weighted average incremental borrowing rate applied was 12%.

The following table presents net lease cost and other supplemental lease information:

	Six Months Ended June 30,	
	2023	2022
Lease cost		
Operating lease cost (cost resulting from lease payments)	\$ 84,014	\$ 81,566
Net lease cost	\$ 84,014	\$ 81,566
Operating lease – operating cash flows (fixed payments)	\$ 84,014	\$ 81,566
Operating lease – operating cash flows (liability reduction)	\$ 67,585	\$ 57,751
Non-current leases – right of use assets	\$ 183,738	\$ 299,783
Current liabilities – operating lease liabilities	\$ 150,480	\$ 128,899
Non-current liabilities – operating lease liabilities	\$ 83,580	\$ 234,060

Future minimum payments under non-cancelable leases for operating leases for the remaining terms of the leases as of June 30, 2023:

Fiscal Year	Operating Leases
Remainder of 2023	\$ 84,014
2024	173,060
Total future minimum lease payments	257,074
Amount representing interest	(23,014)
Present value of net future minimum lease payments	\$ 234,060

#### NOTE 7 – SUBSEQUENT EVENTS

On July 13, 2023, the Company sold an aggregate of 685,033 shares of Common Stock to several institutional buyers and accredited investors in a registered direct offering at an offering price of \$3.03 per share. The offering closed on July 13, 2023, with net proceeds of approximately \$1.8 million. The Company intends to use the net proceeds from the offering in connection with its clinical trials with respect to its lead cell therapy candidate, *BRTX-100*, pre-clinical research and development with respect to its metabolic *ThermoStem Program* and for general corporate purposes and working capital.

## ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

### *Note Regarding Forward-Looking Statements*

This Quarterly Report on Form 10-Q includes a number of forward-looking statements that reflect management's current views with respect to future events and financial performance. Forward-looking statements are projections in respect of future events or our future financial performance. In some cases, you can identify forward-looking statements by terminology such as "may," "should," "expects," "plans," "anticipates," "believes," "estimates," "predicts," "potential" or "continue" or the negative of these terms or other comparable terminology. These statements include statements regarding the intent, belief or current expectations of us and members of our management team, as well as the assumptions on which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risk and uncertainties, and that actual results may differ materially from those contemplated by such forward-looking statements. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, including the risks set forth in the section entitled "Risk Factors" in our Annual Report on Form 10-K for the fiscal year ended December 31, 2022, as filed with the U.S. Securities and Exchange Commission (the "SEC") on March 27, 2023, any of which may cause our company's or our industry's actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied in our forward-looking statements. These risks and factors include, by way of example and without limitation:

- our ability to obtain financing needed to complete our clinical trials and implement our business plan;
- our ability to successfully develop and commercialize BRTX-100, our lead product candidate for the treatment of chronic lumbar disc disease, as well as our metabolic ThermoStem Program;
- our ability to protect our proprietary rights;
- our ability to achieve and sustain profitability of the existing lines of business;
- our ability to attract and retain world-class research and development talent;
- our ability to attract and retain key science, technology and management personnel and to expand our management team;
- the accuracy of estimates regarding expenses, future revenue, capital requirements, profitability, and needs for additional financing;
- business interruptions resulting from geo-political actions, including war and terrorism or disease outbreaks (such as the recent outbreak of COVID-19);
- our ability to attract and retain customers; and
- our ability to navigate through the increasingly complex therapeutic regulatory environment.

Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity or performance. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to actual results.

Readers are urged to carefully review and consider the various disclosures made by us in this report and in our other reports filed with the SEC. We undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes in the future operating results over time, except as required by law. We believe that our assumptions are based upon reasonable data derived from and known about our business and operations. No assurances are made that actual results of operations or the results of our future activities will not differ materially from our assumptions.

As used in this Quarterly Report on Form 10-Q and unless otherwise indicated, the terms "Company," "we," "us" and "our" refer to BioRestorative Therapies, Inc., a Nevada corporation ("BRT"), and its wholly-owned subsidiary, Stem Pearls, LLC, a New York limited liability company ("Stem Pearls"). Unless otherwise specified, all dollar amounts are expressed in United States dollars.



## Intellectual Property

This report includes references to our federally registered trademarks, *BioRestorative Therapies and Dragonfly* design, *BRTX-100*, *ThermoStem*, and *BRTX*. The *Dragonfly* logo is also registered with the U.S. Copyright Office. This report may also include references to trademarks, trade names and service marks that are the property of other organizations. Solely for convenience, trademarks and trade names referred to in this report appear without the ®, SM or TM symbols, and copyrighted content appears without the use of the symbol ©, but the absence of use of these symbols does not reflect upon the validity or enforceability of the intellectual property owned by us or third parties.

## Corporate History

Our offices are located in Melville, New York where we have established a laboratory facility in order to increase our capabilities for the further development of possible cellular-based treatments, products and protocols, stem cell-related intellectual property and translational research applications.

As of June 30, 2023, our accumulated deficit was \$161,305,671. We have historically only generated a modest amount of revenue, and our losses have principally been operating expenses incurred in research and development, marketing and promotional activities in order to commercialize our products and services, plus costs associated with meeting the requirements of being a public company. We expect to continue to incur substantial costs for these activities over at least the next year.

## Business Overview

We develop therapeutic products and medical therapies using cell and tissue protocols, primarily involving adult (non-embryonic) stem cells. We are currently pursuing our *Disc/Spine Program* with our initial investigational therapeutic product being called *BRTX-100*. In March 2022, a United States patent was issued in our *Disc/Spine Program*. We submitted an IND application to the FDA to obtain authorization to commence a Phase 2 clinical trial investigating the use of *BRTX-100*, our lead cell therapy candidate, in the treatment of chronic lower back pain arising from degenerative disc disease. We have received such authorization from the FDA and have commenced such clinical trial through the execution of a CRO agreement with Professional Research Consulting, Inc., d/b/a PRC Clinical ("PRC"), the execution of clinical trial site agreements, patient enrollment, the commencement of patient procedures, the purchase of manufacturing equipment and the expansion of our laboratory to include capabilities for clinical production. We have received a license from the New York State Department of Health to act as a tissue bank for mesenchymal stem cell processing. In June 2023, we received a unanimous recommendation from the Data Safety Monitoring Board ("DSMB") to continue our Phase 2 clinical trial without any changes. We have obtained a license to use technology for investigational adult stem cell treatment of disc and spine conditions, including protruding and bulging lumbar discs. The technology is an advanced stem cell injection procedure that may offer relief from lower back pain, buttock and leg pain, and numbness and tingling in the leg and foot. We are investigating the expansion of the clinic application of *BRTX-100* to other indications within the body.

We are also developing our *ThermoStem Program*. This pre-clinical program involves the use of brown adipose (fat) in connection with the cell-based treatment of type 2 diabetes and obesity as well as hypertension, other metabolic disorders and cardiac deficiencies. United States patents related to the *ThermoStem Program* were issued in September 2015, January 2019, March 2020, March 2021, and July 2021; a notice of allowance was issued in February 2023 by the United States Patent Office for a patent application related to our *ThermoStem Program*; Australian patents related to the *ThermoStem Program* were issued in April 2017, October 2019, and August 2021; Japanese patents related to the *ThermoStem Program* were issued in December 2017, June 2021, and February 2022; a notice of allowance was issued in May 2023 by the Japanese Patent Office for a patent application related to our *ThermoStem Program*; Israeli patents related to our *ThermoStem Program* were issued in October 2019, May 2020, and March 2022; European patents related to the *ThermoStem Program* were issued in April 2020 and January 2021; and a notice of allowance was issued in February 2023 by the European Patent Office for a patent application related to our *ThermoStem Program*.

We have licensed a patented curved needle device that is a needle system designed to deliver cells and/or other therapeutic products or materials to the spine and discs or other potential sites. We anticipate that FDA approval or clearance will be necessary for this device prior to commercialization. We do not intend to utilize this device in connection with our Phase 2 clinical trial with regard to *BRTX-100*.

## Revenue

We derived all of our revenue pursuant to a license agreement with the SCTC entered into in January 2012, as amended in November 2015 and November 2022. Pursuant to the license agreement, the SCTC granted to us an exclusive license to use certain intellectual property related to, among other things, stem cell disc procedures and we have granted to the SCTC a sublicense to use, and the right to sublicense to third parties the right to use, in certain locations in the United States and the Cayman Islands, certain of the licensed intellectual property. In consideration of the sublicenses, the SCTC has agreed to pay us royalties on a per disc procedure basis.

## Results of Operations

### Comparison of the Three Months Ended June 30, 2023 to the Three Months Ended June 30, 2022

Our financial results for the three months ended June 30, 2023 are summarized as follows in comparison to the three months ended June 30, 2022:

	For the Three Months Ended,	
	June 30, 2023	June 30, 2022
	(unaudited)	
<b>Revenues</b>	\$ 64,500	\$ 71,100
<b>Operating expenses:</b>		
Research and development	967,891	1,075,224
General and administrative	2,213,160	3,624,504
Total operating expenses	3,181,051	4,699,728
Loss from operations	(3,116,551)	(4,628,628)
<b>Other (income) expense:</b>		
Interest (income) expense	(96,187)	46,613
Other income, net	(39,812)	-
Total other (income) expense	(135,999)	46,613
<b>Net loss</b>	\$ (2,980,552)	\$ (4,675,241)

#### Revenues

For the three months ended June 30, 2023 and 2022, we generated \$64,500 and \$71,000, respectively, of royalty revenue in connection with our sublicense agreement.

#### Research and Development

Research and development expenses include cash and non-cash compensation of (a) our Vice President of Research and Development; (b) our Scientific Advisory Board members; and (c) laboratory staff and costs related to our brown fat and disc/spine initiatives. Research and development expenses are expensed as they are incurred. For the three months ended June 30, 2023, research and development expenses decreased by \$107,333, or 10.0%, compared to the three months ended June 30, 2022. The decrease was primarily the result of a difference in the timing of payments made for PRC service expenses. A milestone payment in the amount of \$150,000 was paid on June 30, 2022 compared to the three months ended June 30, 2023 in which no milestone payment was due.

We expect that our research and development expenses will increase in subsequent fiscal periods.

#### General and Administrative

General and administrative expenses consist primarily of salaries, bonuses, payroll taxes and stock-based compensation to employees, as well as corporate expenses such as legal and professional fees, investor relations and occupancy-related expenses. For the three months ended June 30, 2023, general and administrative expenses decreased by \$1,411,344, or 38.9%, as compared to the three months ended June 30, 2022, primarily driven by a \$1,618,481 decrease in stock-based compensation.

#### Interest (income) expense

For the three months ended June 30, 2023, interest income was \$96,187 compared to interest expense of \$46,613 for the three months ended June 30, 2022. The change was primarily due to our investments in marketable securities during the three months ended June 30, 2023, which generated interest income. During the three months ended June 30, 2022, we did not have any such investments and only incurred interest expense.

#### Other income, net

For the three months ended June 30, 2023, Other income, net primarily relates to gains from settlements of certain accrued expenses and realized and unrealized gain on investments.

## Comparison of the Six Months Ended June 30, 2023 to the Six Months Ended June 30, 2022

Our financial results for the six months ended June 30, 2023 are summarized as follows in comparison to the six months ended June 30, 2022:

	For the Six Months Ended,	
	June 30, 2023	June 30, 2022
	<i>(unaudited)</i>	
<b>Revenues</b>	\$ 95,800	\$ 87,100
<b>Operating expenses:</b>		
Research and development	2,479,136	1,850,561
General and administrative	6,512,313	7,918,960
Total operating expenses	8,991,449	9,769,521
Loss from operations	(8,895,649)	(9,682,421)
<b>Other (income) expense:</b>		
Interest (income) expense	(114,403)	75,624
Gain on PPP loan forgiveness	-	(250,000)
Grant income	-	(16,654)
Other income, net	(116,472)	-
Total other income	(230,875)	(191,030)
<b>Net loss</b>	\$ (8,664,774)	\$ (9,491,391)

### Revenues

For the six months ended June 30, 2023 and 2022, we generated \$95,800 and \$87,100, respectively, of royalty revenue in connection with our sublicense agreement.

### Research and Development

Research and development expenses include cash and non-cash compensation of (a) our Vice President of Research and Development; (b) our Scientific Advisory Board members; and (c) laboratory staff and costs related to our brown fat and disc/spine initiatives. Research and development expenses are expensed as they are incurred. For the six months ended June 30, 2023, research and development expenses increased by \$628,575, or 34.0%, compared to the six months ended June 30, 2022. The increase was primarily driven by increased salaries and wages of \$836,000, increased lab site fees of \$84,000, and increased consulting fees of 95,000, offset by a decrease in PRC service expenses of \$532,000.

We expect that our higher level of research and development expenses will continue in subsequent fiscal periods.

### General and Administrative

General and administrative expenses consist primarily of salaries, bonuses, payroll taxes and stock-based compensation to employees, as well as corporate expenses such as legal and professional fees, investor relations and occupancy-related expenses. For the six months ended June 30, 2023, general and administrative expenses decreased by \$1,406,647, compared to the six months ended June 30, 2022. The decrease was primarily driven by a \$1,655,195 decrease in stock-based compensation, offset by an increase in salaries and wages of \$167,000.

We expect that our general and administrative expenses will increase as we expand our staff, develop our infrastructure and incur additional costs to support the growth of our business.

### Interest (income) expense

For the six months ended June 30, 2023, interest income was \$114,403 compared to interest expense of \$75,624 for the six months ended June 30, 2022. The change was primarily due to our investments in marketable securities during the six months ended June 30, 2023, which generated interest income. During the six months ended June 30, 2022, we did not have any such investments and only incurred interest expense.

#### Other income, net

For the six months ended June 30, 2023, Other income, net primarily relates to gains from settlements of certain accrued expenses and realized and unrealized gain on investments.

#### Gain on PPP loan forgiveness

Under the terms of the U.S. Small Business Administration's Paycheck Protection Program ("PPP"), our \$250,000 PPP loan was forgiven during the six months ended June 30, 2022.

#### Grant income

Grant income of \$16,654 during the six months ended June 30, 2022 consists of funding received under a \$256,000 National Institutes of Health Small Business Technology Transfer (STTR) Phase 1 grant, which we were awarded in September 2021. There was no grant income during the six months ended June 30, 2023.

#### *Liquidity and Capital Resources*

##### **Liquidity**

We measure our liquidity in a number of ways, including the following:

	<b>June 30, 2023</b>	<b>December 31, 2022</b>
Cash, Cash Equivalents, and Investments	\$ 11,615,365	\$ 14,749,408
Working Capital	\$ 11,231,071	\$ 14,688,188

Working capital decreased by \$3,457,117 primarily due to the \$3,479,065 of cash used to fund our operations.

##### **Availability of Additional Funds**

Based upon our accumulated deficit of \$161,305,671 as of June 30, 2023, along with our forecast for continued operating losses and our need for financing to fund our current and contemplated clinical trials, we will eventually require additional equity and/or debt financing to continue our operations. However, based on cash on hand as of June 30, 2023 and the recent offerings discussed below, we believe we have sufficient cash to fund operations for the twelve months subsequent to the filing date of this Form 10-Q.

Our operating needs include the planned costs to operate our business, including amounts required to fund our clinical trials, working capital and capital expenditures. Our future capital requirements and the adequacy of our available funds will depend on many factors, including our ability to successfully commercialize our products and services, competing technological and market developments, and the need to enter into collaborations with other companies or acquire other companies or technologies to enhance or complement our product and service offerings.

We may be unable to raise sufficient additional capital when we need it or raise capital on favorable terms. Future financing may require us to pledge certain assets and enter into covenants that could restrict certain business activities or our ability to incur further indebtedness and may contain other terms that are not favorable to our stockholders or us. If we are unable to obtain adequate funds on reasonable terms, we may be required to significantly curtail or discontinue operations or obtain funds by entering into financing agreements on unattractive terms.

##### **"At-the-Market" Offering**

In April 2023, we entered into a Capital on Demand Sales Agreement with JonesTrading Institutional Services LLC (the "Sales Agent") under which we have the ability to issue and sell shares of our Common Stock, from time to time, through the Sales Agent, up to an aggregate offering price of \$4,200,000 in what is commonly referred to as an "at-the-market" ("ATM") program. During the three months ended June 30, 2023, we sold 93,551 shares of our Common Stock under the ATM program with the Sales Agent at a weighted-average gross price of approximately \$5.74 per share and raised approximately \$536,600 of gross proceeds. The total commissions and related legal fees were approximately \$125,000, and we received net proceeds of approximately \$412,000. As of June 30, 2023, we had remaining capacity to sell up to an additional \$3,663,407 of Common Stock under the ATM program.

## Registered Direct Offering

In July 2023, we sold an aggregate of 685,033 shares of our Common Stock in a registered direct offering. We received net proceeds of approximately \$1,831,000 from the offering.

## Cash Flows

During the six months ended June 30, 2023 and 2022, our sources and uses of cash were as follows:

	Six Months Ended June 30,	
	2023	2022
Net cash used in operating activities	\$ (3,479,065)	\$ (2,845,765)
Net cash provided by (used in) investing activities	3,174,433	(247,247)
Net cash provided by financing activities	411,701	-
Net increase (decrease) in cash	\$ 107,069	\$ (3,093,003)

## Operating Activities

Net cash used in operating activities was \$3,479,065 for the six months ended June 30, 2023, primarily due to cash used to fund the net loss of \$8,664,774, which was partially offset by non-cash expenses of \$4,824,865 related primarily to stock-based compensation. Cash flows were also impacted by routine fluctuations in our operating assets and liabilities. Net cash used in operating activities was \$2,845,756 for the six months ended June 30, 2022, primarily due to cash used to fund the net loss of \$9,491,391 and a non-cash gain of \$250,000 on forgiveness of our PPP loan, which were partially offset by non-cash expenses of \$6,480,055 related primarily to stock-based compensation and \$300,032 of cash provided by changes in the levels of operating assets and liabilities.

## Investing Activities

Net cash provided by investing activities increased by \$3,421,680 for the six months ended June 30, 2023 compared to the six months ended June 30, 2022, primarily due to a sale of marketable securities, which provided \$3,263,504 of cash.

## Financing Activities

Net cash provided by financing activities increased by \$411,701 for the six months ended June 30, 2023 compared to the six months ended June 30, 2022, due to the net proceeds from the ATM offerings of the Company's Common Stock.

## Effects of Inflation

We do not believe that inflation had a material impact on our business, revenues or operating results during the periods presented.

Our significant accounting policies are more fully described in the notes to our unaudited condensed consolidated financial statements included herein for the quarter ended June 30, 2023, and in the notes to our audited consolidated financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC on March 27, 2023.

### **ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK**

Not applicable. As a smaller reporting company, we are not required to provide the information required by this Item.

### **ITEM 4. CONTROLS AND PROCEDURES**

#### **Evaluation of Disclosure Controls and Procedures**

We maintain disclosure controls and procedures as that term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (“the Exchange Act”), that are designed to ensure that information required to be disclosed in our reports under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosures. In designing disclosure controls and procedures, our management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Any controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute, assurance of achieving the desired control objectives.

Under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, we are required to perform an evaluation of our disclosure controls and procedures, as such term is defined in Rule 13a-15(e) under the Exchange Act, as of June 30, 2023.

Management has completed such evaluation and has concluded that our disclosure controls and procedures were not effective to provide reasonable assurance that information required to be disclosed by us in reports we file or submit under the Exchange Act is appropriate to allow timely decisions regarding required disclosures. As a result of the material weakness in internal controls over financial reporting described below, we concluded that our disclosure controls and procedures as of June 30, 2023 were not effective.

#### **Material Weaknesses in Internal Control over Financial Reporting**

Management assessed the effectiveness of our internal control over financial reporting as of June 30, 2023 based on the framework established in Internal Control—Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on this assessment, management has determined that our internal control over financial reporting as of June 30, 2023 was not effective.

A material weakness, as defined in the standards established by Sarbanes-Oxley, is a deficiency, or a combination of deficiencies, in internal control over financial reporting such that there is a reasonable possibility that a material misstatement of our annual or interim consolidated financial statements will not be prevented or detected on a timely basis.

The ineffectiveness of our internal control over financial reporting was due to the following material weaknesses:

- Lack of adherence to formal policies and procedures;
- Lack of risk assessment procedures on internal controls to detect financial reporting risks in a timely manner; and
- Lack of sufficient formal management testing over documented formal procedures and controls, and time to evaluate continuous effectiveness of controls to achieve complete and accurate financial reporting and disclosures, including documented controls over the preparation and review of journal entries and account reconciliations.

## **Management's Plan to Remediate the Material Weaknesses**

Management has been implementing and continues to implement measures designed to ensure that control deficiencies contributing to the material weaknesses are remediated, such that these controls are designed, implemented, and operating effectively. The remediation actions include:

- New management personnel, including our Chief Financial Officer, who is overseeing the financial reporting process and implementation of enhanced controls and governance;
- Engagement of external financial consulting firm to continue to enhance financial reporting, financial operations and internal controls; and
- Documentation of key procedures and controls using a risk-based approach.

Management is committed to maintaining a strong internal controls environment and implementing measures designed to help ensure that control deficiencies contributing to the material weaknesses are remediated as soon as possible. We have documented key procedures and controls using a risk-based approach and have, therefore, made progress toward remediation. We continue to implement our remediation plan, which includes continued engagement of an external financial consulting firm to enhance financial reporting and operations as well as design and implementation of controls. We will consider the material weaknesses remediated after the applicable controls operate for a sufficient period of time, and Management has concluded, through testing, that the controls are operating effectively.

Management will continue to monitor and evaluate the effectiveness of our internal controls and procedures over financial reporting on an ongoing basis and is committed to taking further action and implementing additional enhancements or improvements, as necessary and as funds allow.

## **Changes in Internal Control Over Financial Reporting**

Other than described above, there have been no changes in our internal control over financial reporting that occurred during our second quarter of 2023 that have materially affected, or that are reasonably likely to materially affect, our internal control over financial reporting.

## **PART II - OTHER INFORMATION**

### **ITEM 1A. RISK FACTORS**

An investment in our Common Stock involves a number of very significant risks. You should carefully consider the risk factors included in the "Risk Factors" section of our Annual Report on Form 10-K for the year ended December 31, 2022, as filed with the SEC on March 27, 2023, in addition to other information contained in that report and in this quarterly report in evaluating the Company and its business before purchasing shares of our Common Stock. The Company's business, operating results and financial condition could be adversely affected due to any of those risks.

### **ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS**

During the three months ended June 30, 2023, we did not have any unregistered sales of equity securities.

# ITEM 6. EXHIBITS

Exhibit Number	Exhibit Description	Incorporated by Reference		
		Form	Exhibit	Filing Date
3.1	<a href="#">Amended and Restated Articles of Incorporation</a>	8-K	3.3	1/5/2023
3.2	<a href="#">Certificate of Designations of Preferred Stock (Series B)</a>	8-K	3.4	1/5/2023
3.3	<a href="#">Bylaws</a>	8-K	3.5	1/5/2023
31.1*	<a href="#">Certification of Principal Executive Officer</a>			
31.2*	<a href="#">Certification of Principal Financial Officer</a>			
32.1**	<a href="#">Section 1350 Certification of Principal Executive Officer and Principal Financial Officer</a>			
101.INS	Inline XBRL Instance Document			
101.SCH	Inline XBRL Taxonomy Extension Schema Document			
101.CAL	Inline XBRL Taxonomy Extension Calculation Linkbase Document			
101.DEF	Inline XBRL Taxonomy Extension Definition Linkbase Document			
101.LAB	Inline XBRL Taxonomy Extension Label Linkbase Document			
101.PRE	Inline XBRL Taxonomy Extension Presentation Linkbase Document			
104	Cover Page Interactive Data File (embedded within the Inline XBRL document)			

\* Filed herewith.

\*\* In accordance with SEC Release 33-8238, Exhibit 32.1 is being furnished and not filed.



## SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

### BIORESTORATIVE THERAPIES, INC.

By: /s/ Lance Alstodt  
Lance Alstodt  
Chief Executive Officer, President, and Chairman of the Board  
(Principal Executive Officer)  
Date: August 11, 2023

By: /s/ Robert E. Kristal  
Robert E. Kristal  
Chief Financial Officer  
(Principal Financial Officer)  
Date: August 11, 2023

## SECTION 302 CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

I, Lance Alstodt, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of BioRestorative Therapies, Inc.
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 11, 2023

/s/ Lance Alstodt

Lance Alstodt

Principal Executive Officer

---

## SECTION 302 CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER

I, Robert Kristal, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of BioRestorative Therapies, Inc.
2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report.
3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report.
4. The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
  - (a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
  - (b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
  - (c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and
  - (d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting.
5. The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):
  - (a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and
  - (b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: August 11, 2023

*/s/ Robert Kristal*

Robert Kristal

Principal Financial Officer

---

**CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER  
AND PRINCIPAL FINANCIAL OFFICER  
PURSUANT TO  
18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO  
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002**

Pursuant to 18 U.S.C. § 1350, the undersigned officers of BioRestorative Therapies, Inc. (the “Company”) hereby certify that the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2023 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: August 11, 2023

*/s/ Lance Alstodt*

\_\_\_\_\_  
Lance Alstodt  
Principal Executive Officer

*/s/ Robert Kristal*

\_\_\_\_\_  
Robert Kristal  
Principal Financial Officer

The foregoing certification is being furnished solely pursuant to 18 U.S.C. § 1350 and is not being filed as part of the Report or as a separate disclosure document.

---